Navigation Links
Caliper Life Sciences Reports First Quarter 2009 Results
Date:4/30/2009

approximately 6%. Research growth was strong, primarily due to sales of the proprietary LabChip GX, which the Company believes is the "best-in-class" proprietary solution for characterizing proteins in the fast growing biologicals market, and increased sales of Profiler Pro reagent kits which are used for kinase screening with the EZ Reader instrument.
  • Optical Imaging revenues increased to $10.7 million during the first quarter of 2009 from $9.8 million during the first quarter of 2008. This increase represented organic growth of 15% before unfavorable currency effects of approximately 5%. Optical Imaging growth was driven by continued strong global demand for IVIS instruments and accessories, reagents and services.
  • Caliper's Discovery Alliances and Services (CDAS) revenues decreased by 7% (unaffected by currency changes) to $4.2 million during the first quarter of 2009 from $4.5 million during the first quarter of 2008. The net decrease resulted from a decrease in in vitro services revenues partially offset by in vivo services revenue improvement. The Company anticipates revenue from CDAS services to grow over the second half of 2009 based on the expectation that it will receive a new task order under the Environmental Protection Agency's ToxCast(R) program.
  • Total gross margin decreased by approximately 1% during the first quarter of 2009 compared to same period in 2008 primarily due to the loss of service margin contribution that was associated with the product lines that were divested in the fourth quarter of 2008.
  • Operating expenses (research and development plus selling, general and administrative expenses) decreased by 19% to $15.7 million during the first quarter of 2009 from $19.5 million in the first quarter of 2008. This reduction included $2.8 million of SG&A expense reduction and $1.0 million of R&D expense reduction resulting from streamlining
    '/>"/>

  • SOURCE Caliper Life Sciences, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
    2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
    3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
    4. Caliper Life Sciences Presentation at UBS Global Life Sciences Conference to be Webcast
    5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
    6. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
    7. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
    8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
    9. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
    10. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
    11. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
    (Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ( ... cell biotechnologies. Currently the company holds seven recently ... applications currently under examination by the U.S. Patent and ... the most vexing problems in adult stem cell biology ... difficult to identify; and they have been difficult to ...
    (Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
    (Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
    Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
    ... A ... Biology are Natural Partners in the Fight Against Disorder. , ... (PRWEB) November 3, 2009 -- MyPhield Technology ... naturally relieves osteoarthritis without causing unwanted side-effects, is now available online at www.ReliefForLife.ca ...
    ... 3 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... 30, 2009. ISTA reported net revenue of $32.0 million ... increase over net revenue for the three months ended September ... months ended September 30, 2009 is $1.2 million associated with ...
    ... SAN MARCOS, Texas, Nov. 3 Texas State University ... agreement today that will permit University Researchers to continue ... potential and effectiveness of ALKA-V6, a compound which has ... the HIV virus in laboratory experiments. , The research ...
    Cached Biology Technology:New Technology Now Available In Canada For Osteoarthritis 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 2Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 3
    (Date:7/31/2014)... brown and beige adipocytes, or fat cells, are inherently ... and each plays its own role in metabolism. In ... the most prevalent. Its primary function is energy storage. ... to generate heat but are only found in a ... which represent a special type of brown adipocytes, appear ...
    (Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
    (Date:7/30/2014)... change on the world,s animal and plant species ... a new paper by a research team from ... other organizations. The authors claim that most of ... it comes to climate change. , While ... the "direct" threats of changing temperatures and precipitation ...
    Breaking Biology News(10 mins):Hope for the overweight 2Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
    ... 23 GenVault Corporation, the leader in ambient temperature ... announced that David Wellis, Ph.D., GenVault,s President and CEO, ... place on October 26th and 27th in La Jolla, ... an overview of the company together with recent customer, ...
    ... HILL Scientists at the University of North Carolina ... of California, San Francisco have developed and experimentally tested ... drugs. The researchers developed a computational method that ... are to the naturally occurring binding partners -- known ...
    ... MADISON, WI, NOVEMBER 4, 2009 -- The world,s greatest wines ... input, and something called the "terroir" -- a term often defined ... will discuss terroir with an emphasis on soil science in a ... the Environment" will be presented in two parts at the 2009 ...
    Cached Biology News:GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Study points to new uses, unexpected side effects of already existing drugs 2Great wines come from great soils 2